Replies to post #317347 on Avid Bioservices Inc (CDMO)

[biopharm]

..We went through this hypothetical exercise the other day, decided $15-25/ share might be reasonable for most SHs to accept in present circumstances given what we know about state of just PPHM technology. We left Avid out of that equation, leaving it to stand alone.

North, I don't believe we know the exact state of PPHM Technology but we know it is advancing and PS must be targeted, we also do not exactly know all collaborations and we do know there is some amount of quiet going on etc etc

My comparison goes back to Genentech drugs which offered NO safety and actually, I bet if the current Biomarkers known now and becoming known, IF used back during those Genentech days, Roche paid for drugs that do not hear the immune system and actually were doing more harm than good

The PS Targeting platform now, brings forth a platform never seen before and the new knowledge being learned will make 1 or 2 or 5 Billion market cap look like a steal for anyone looking to pick up PS Targeting...

I stick with my starting point of $21 Billion, especially with some GE Healthcare to Ronin to Dart Executions ties I am seeing

We should be easily passed Sept 2012 highs (in relation to market cap ) right now and I see all games being played till we hit $35 or so and we only tee off from there whole #1 with 17 to go but will Peregrine try to sell out like Medarex did? Interesting times